

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	7	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	33	MAY 21	CA/CAPLUS enhanced with additional kind codes for German patents
NEWS	34	MAY 22	CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:31:44 ON 13 JUN 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:31:57 ON 13 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUN 2007 HIGHEST RN 937161-92-7

DICTIONARY FILE UPDATES: 12 JUN 2007 HIGHEST RN 937161-92-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10528270.str



chain nodes :
 10 11 15 22 23 24 25 26
 ring nodes :
 1 2 3 4 5 6 7 8 9 16 17 18 19 20 21
 ring/chain nodes :
 12
 chain bonds :
 4-12 6-11 8-10 11-15 12-22 15-16 22-23 22-25 23-24 25-26
 ring bonds :
 1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 16-17 16-21 17-18 18-19 19-20
 20-21
 exact/norm bonds :
 2-7 4-12 6-11 7-8 8-10 11-15 12-22 23-24 25-26
 exact bonds :
 3-9 8-9 15-16 22-23 22-25
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21
 isolated ring systems :
 containing 1 :

G1:H,CH3

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 18:32:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED

5. ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:

ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

5 TO 234

PROJECTED ANSWERS:

0 TO 0

L2

0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:32:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 120 TO ITERATE

100.0% PROCESSED

120 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

L3

14 SEA SSS FUL L1

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 18:32:32 ON 13 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jun 2007 VOL 146 ISS 25
FILE LAST UPDATED: 12 Jun 2007 (20070612/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 4 L3

=> d l4 ibib hitstr abs 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:547606 CAPLUS

DOCUMENT NUMBER: 143:78206

TITLE: Process for preparation of 5-difluorobenzylthio-7-aminothiazolo[4,5-d]pyrimidin-2(3H)-ones via protection and amination reactions.

INVENTOR(S): Butters, Michael; Wisedale, Richard; Thomson, Colin; Welham, Matthew James; Watts, Andrew

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056563	A2	20050623	WO 2004-GB5072	20041202
WO 2005056563	A3	20050825		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004296241	A1	20050623	AU 2004-296241	20041202
CA 2546719	A1	20050623	CA 2004-2546719	20041202
EP 1711505	A2	20061018	EP 2004-801262	20041202
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
CN 1914213	A	20070214	CN 2004-80041445	20041202
BR 2004017300	A	20070306	BR 2004-17300	20041202

JP 2007513131
NO 2006003111
PRIORITY APPLN., INFO.:

T 20070524
A 20060905

JP 2006-542009
NO 2006-3111
GB 2003-28243
WO 2004-GB5072

20041202
20060704
A 20031205
W 20041202

OTHER SOURCE(S): MARPAT 143:78206


IT 676345-23-6P 855476-57-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)

(claimed compound; preparation of
difluorobenzylthioaminothiazolopyrimidinones
via protection and amination reactions)

RN 676345-23-6 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-
[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monosodium salt (9CI)
(CA INDEX NAME)



● Na



RN 855476-57-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-
[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monopotassium salt
(9CI) (CA INDEX NAME)



● K

GI



AB Title compds. I [R1 = (substituted) carbocyclyl, alkyl, alkenyl, alkynyl, aryl, heteroaryl; R2, R3 = H, (substituted) alkyl, carbocyclyl, alkenyl, alkynyl], were prepared by treatment of precursors II (R1 as above; L = leaving group; Q = H) with a protecting reagent to give I; (R1, L as above; Q = protecting group), treatment of the latter with HNR2R3 (R2, R3 as above), and deprotection. Thus, 7-chloro-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2(3H)-one (preparation given) and p-TsOH in PhMe at 60° was treated with 3,4-dihydropyran over 1 h and maintained at 60° for 2 h. The mixture was cooled, stirred with aqueous NaHCO3 and then brine and the resulting solution was heated

with THF, Na2CO3, and D-alaninol followed by heating at 60° for 11.5 h and at 65° for 24 h to give 5-[[2,3-difluorophenyl)methyl]thio]-7-[[1R)-2-hydroxy-1-methylethyl]amino]-3-(tetrahydro-2H-pyran-2-yl)thiazolo[4,5-d]pyrimidin-2(3H)-one. The latter in MeCN/H2O/THF at 65° was treated with 1N HCl over 3 h to give 5-[[2,3-difluorophenyl)methyl]thio]-7-[[1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267340 CAPLUS

DOCUMENT NUMBER: 140:303689

TITLE: Preparation of 5-[[2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist

INVENTOR(S): Bonnert, Roger Victor

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026880	A1	20040401	WO 2003-GB3998	20030916
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2498762	A1	20040401	CA 2003-2498762	20030916
AU 2003267571	A1	20040408	AU 2003-267571	20030916
EP 1543013	A1	20050622	EP 2003-748263	20030916
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

BR 2003014844	A	20050809	BR 2003-14844	20030916
CN 1681826	A	20051012	CN 2003-822335	20030916
JP 2006503835	T	20060202	JP 2004-537276	20030916
NZ 538826	A	20061222	NZ 2003-538826	20030916
ZA 2005002272	A	20050919	ZA 2005-2272	20050317
NO 2005001892	A	20050617	NO 2005-1892	20050419
US 2006100221	A1	20060511	US 2005-528316	20051201
PRIORITY APPLN. INFO.:			GB 2002-21828	A 20020920
			WO 2003-GB3998	W 20030916

OTHER SOURCE(S): MARPAT 140:303689


IT 676345-22-5P 676345-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(multi-step preparation of 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)


RN 676345-22-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]- (9CI) (CA INDEX NAME)



RN 676345-23-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


IT 676345-26-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(multi-step preparation of 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)

RN 676345-26-9 CAPLUS

CN 1,3-Propanediol, 2-[[5-[[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I and its monosodium salt, useful for treating a chemokine mediated diseases such as asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, cancer, etc., were prepared in a multi-step process, starting from 4-amino-6-hydroxy-2-mercaptopyrimidine and 2,3-difluorobenzyl bromide. The compound I showed IC₅₀ of < 10 µM against hrCXCR2 binding. The latter was also tested in intracellular calcium mobilisation assay and found to be an antagonist of the CXCR2 receptor in human neutrophils. A process for the preparation of the compound I which comprises reaction of II [R = alkyl] with an acid is claimed. The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267303 CAPLUS

DOCUMENT NUMBER: 140:303685

TITLE: Preparation of 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist

INVENTOR(S): Brough, Stephen John; McInally, Thomas

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026835	A1	20040401	WO 2003-GB4000	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2498760	A1	20040401	CA 2003-2498760	20030916
AU 2003264765	A1	20040408	AU 2003-264765	20030916
EP 1542974	A1	20050622	EP 2003-797377	20030916

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003014843	A	20050809	BR 2003-14843	20030916
CN 1681787	A	20051012	CN 2003-822336	20030916
JP 2006503836	T	20060202	JP 2004-537278	20030916
ZA 2005002267	A	20050919	ZA 2005-2267	20050317
US 2005272750	A1	20051208	US 2005-528270	20050317
NO 2005001893	A	20050617	NO 2005-1893	20050419

PRIORITY APPLN. INFO.: GB 2002-21829 A 20020920
WO 2003-GB4000 W 20030916

OTHER SOURCE(S): MARPAT 140:303685

IT 676345-69-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(multi-step preparation of 5-[(2,3-difluorophenyl)methyl]thio]-7-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino)thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)

RN 676345-69-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2,3-difluorophenyl)methyl]thio]-7-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I, useful for treating a chemokine mediated diseases such as asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, cancer, etc., was prepared in a 7-step process, starting from 4-amino-6-hydroxy-2-mercaptopyrimidine and 2,3-difluorobenzyl bromide. The compound I showed IC50 of < 10 μ M against hrCXCR2 binding. The latter was also tested in intracellular calcium mobilisation assay and found to be an antagonist of the CXCR2 receptor in human neutrophils. A process for the preparation of the compound I which comprises reaction of II [R = alkyl] with an acid is

claimed. The pharmaceutical composition comprising the compound I is claimed.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:265425 CAPLUS
DOCUMENT NUMBER: 134:280857
TITLE: Preparation of novel thiazolo[4,5-d]pyrimidines as
modulators of chemokine receptors
INVENTOR(S): Willis, Paul Andrew; Bonnert, Roger Victor; Hunt,
Simon Fraser; Walters, Iain Alistair Stewart
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025242	A1	20010412	WO 2000-GB3692	20000926
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2385269	A1	20010412	CA 2000-2385269	20000926
BR 2000014334	A	20020611	BR 2000-14334	20000926
EP 1222195	A1	20020717	EP 2000-960891	20000926
EP 1222195	B1	20040114		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003511384	T	20030325	JP 2001-528186	20000926
EE 200200174	A	20030415	EE 2002-174	20000926
HU 200204246	A2	20030428	HU 2002-4246	20000926
NZ 517880	A	20030926	NZ 2000-517880	20000926
EP 1348709	A2	20031001	EP 2003-15019	20000926
EP 1348709	A3	20031119		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
AT 257838	T	20040115	AT 2000-960891	20000926
PT 1222195	T	20040531	PT 2000-960891	20000926
ES 2213043	T3	20040816	ES 2000-960891	20000926
AU 777872	B2	20041104	AU 2000-73049	20000926
TW 260324	B	20060821	TW 2000-89121952	20001019
IN 2002MN00313	A	20050318	IN 2002-MN313	20020314
NO 2002001448	A	20020522	NO 2002-1448	20020322
ZA 2002002380	A	20030804	ZA 2002-2380	20020325
US 6790850	B1	20040914	US 2002-89571	20020329
HK 1052009	A1	20060113	HK 2003-104330	20030617
US 2004224961	A1	20041111	US 2004-863995	20040609
PRIORITY APPLN. INFO.:			SE 1999-3544	A 19991001
			EP 2000-960891	A3 20000926
			WO 2000-GB3692	W 20000926
			US 2002-89571	A1 20020329

OTHER SOURCE(S): MARPAT 134:280857


IT 333742-86-2P 333742-87-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)


RN 333742-86-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(methoxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 333742-87-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




IT 333742-50-0P 333742-72-6P 333742-91-9P
333742-92-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 333742-50-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 333742-72-6 CAPLUS

CN Propanamide, 2-[[5-[[[(2,3-difluorophenyl)methyl]thio]-2,3-dihydro-2-


oxothiazolo[4,5-d]pyrimidin-7-yl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-91-9 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(methoxymethyl)ethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 333742-92-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[(phenylmethyl)thio]-, monosodium salt (9CI) (CA INDEX NAME)




● Na


IT 333743-09-2P 333743-99-0P 333744-02-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine
 receptors)
 RN 333743-09-2 CAPLUS
 CN 1,3-Propanediol, 2-[[5-[[[(2,3-difluorophenyl)methyl]thio]-2-
 methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-99-0 CAPLUS
 CN 1-Propanol, 2-[[5-[[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-
 d]pyrimidin-7-yl]amino]-3-methoxy- (9CI) (CA INDEX NAME)



RN 333744-02-8 CAPLUS
 CN 1,3-Propanediol, 2-[[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-
 d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2, R3 = H, alkyl, cycloalkyl, etc.], useful in treating a chemokine mediated disease, were prepared E.g., a multi-step synthesis of I [R1 = CH2Ph; R2 = CMe2CH2OH; R3 = H] was described. The compds. I were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.55	193.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

STN INTERNATIONAL LOGOFF AT 18:32:49 ON 13 JUN 2007